Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 267

1.

Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.

Plaza Z, Soriano V, Vispo E, del Mar Gonzalez M, Barreiro P, Seclén E, Poveda E.

Antivir Ther. 2012;17(5):921-6. doi: 10.3851/IMP2091.

PMID:
22436385
2.

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.

Fridell RA, Qiu D, Wang C, Valera L, Gao M.

Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50. doi: 10.1128/AAC.00556-10.

3.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.

J Clin Virol. 2012 Aug;54(4):352-4. doi: 10.1016/j.jcv.2012.04.024.

PMID:
22658798
4.

NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus.

Peres-da-Silva A, de Almeida AJ, Lampe E.

J Antimicrob Chemother. 2015 Mar;70(3):726-30. doi: 10.1093/jac/dku462.

5.

Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.

Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R, Quarleri J.

Antiviral Res. 2012 Aug;95(2):72-81. doi: 10.1016/j.antiviral.2012.05.015.

PMID:
22683884
6.

Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.

McCormick AL, Wang L, Garcia-Diaz A, Macartney MJ, Webster DP, Haque T.

Antivir Ther. 2015;20(1):81-5. doi: 10.3851/IMP2763.

PMID:
24621453
7.

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.

Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H.

J Hepatol. 2013 Apr;58(4):646-54. doi: 10.1016/j.jhep.2012.11.012.

PMID:
23178977
8.

Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.

Lindström I, Kjellin M, Palanisamy N, Bondeson K, Wesslén L, Lannergard A, Lennerstrand J.

Infect Dis (Lond). 2015 Aug;47(8):555-62. doi: 10.3109/23744235.2015.1028097.

PMID:
25851241
9.

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.

Trimoulet P, Belzunce C, Faure M, Wittkop L, Reigadas S, Dupon M, Ragnaud JM, Fleury H, Neau D.

HIV Med. 2011 Sep;12(8):506-9. doi: 10.1111/j.1468-1293.2011.00913.x.

10.

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.

McPhee F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, Yu ML, Ahn SH, Ishikawa H, Bhore R, Zhou N, Hernandez D, Mendez P, Kumada H.

Adv Ther. 2015 Jul;32(7):637-49. doi: 10.1007/s12325-015-0221-5.

11.

Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.

Uchida Y, Kouyama J, Naiki K, Sugawara K, Ando S, Nakao M, Motoya D, Inao M, Imai Y, Nakayama N, Mochida S.

J Gastroenterol. 2016 Mar;51(3):260-70. doi: 10.1007/s00535-015-1106-8.

PMID:
26245700
12.

HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b.

Hirotsu Y, Kanda T, Matsumura H, Moriyama M, Yokosuka O, Omata M.

Hepatol Int. 2015 Jul;9(3):424-30. doi: 10.1007/s12072-015-9624-2.

PMID:
25791176
13.

Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.

Vicenti I, Rosi A, Saladini F, Meini G, Pippi F, Rossetti B, Sidella L, Di Giambenedetto S, Almi P, De Luca A, Caudai C, Zazzi M.

J Antimicrob Chemother. 2012 Apr;67(4):984-7. doi: 10.1093/jac/dkr581.

14.

Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.

Sede M, Laufer N, Ojeda D, Gun A, Cahn P, Quarleri J.

Arch Virol. 2013 Sep;158(9):1907-15. doi: 10.1007/s00705-013-1687-6.

PMID:
23553458
15.

Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.

Kosaka K, Imamura M, Hayes CN, Abe H, Hiraga N, Yoshimi S, Murakami E, Kawaoka T, Tsuge M, Aikata H, Miki D, Ochi H, Matsui H, Kanai A, Inaba T, Chayama K.

J Viral Hepat. 2015 Feb;22(2):158-65. doi: 10.1111/jvh.12271.

PMID:
24943406
16.

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.

McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D.

Hepatology. 2013 Sep;58(3):902-11. doi: 10.1002/hep.26388.

PMID:
23504694
17.

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Roberts S, Fridell RA, Gao M.

Antimicrob Agents Chemother. 2013 May;57(5):2054-65. doi: 10.1128/AAC.02494-12.

18.

Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.

Wang C, Jia L, O'Boyle DR 2nd, Sun JH, Rigat K, Valera L, Nower P, Huang X, Kienzle B, Roberts S, Gao M, Fridell RA.

Antimicrob Agents Chemother. 2014 Sep;58(9):5155-63. doi: 10.1128/AAC.02788-14.

19.

Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.

Yoshimi S, Imamura M, Murakami E, Hiraga N, Tsuge M, Kawakami Y, Aikata H, Abe H, Hayes CN, Sasaki T, Ochi H, Chayama K.

J Med Virol. 2015 Nov;87(11):1913-20. doi: 10.1002/jmv.24255.

PMID:
25954851
20.

Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.

Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F.

J Clin Virol. 2013 May;57(1):13-8. doi: 10.1016/j.jcv.2012.12.020. Erratum in: J Clin Virol. 2016 Apr;77:115.

PMID:
23384816
Items per page

Supplemental Content

Support Center